Document is current
Any future updates will be listed below
-
Authors
Agarwal, Prabhat K
Bhushan, Divendu
Bhate, Amit
Naik, Sunil
Adwani, Shailesh
Kushwaha, J S
Bhushan, Sumit
Mane, Abhishek
Gadkari, Rujuta
Choudhari, Sanjay
Patil, Saiprasad
Barkate, Hanmant
- License Information
-
More Information
Article History
Received: 16 September 2024
Accepted: 24 October 2024
First Online: 18 December 2024
Declarations
:
: The work presented in this study was in accordance with the study protocol, the New Drugs and Clinical Trials Rules 2019 issued by the Government of India, the ethical principles that have their origin in the Declaration of Helsinki, International Council for Harmonisation (ICH) Good Clinical Practice (GCP), and all applicable local regulatory requirements. Informed consent was obtained from all the study subjects who took part in the trial. Ethic committee approval was obtained from all respective sites and study was registered in CTRI (CTRI/2022/05/042581).
: We, hereby transfer all copyright ownership of the manuscript entitled " A Prospective, Multicentre Study Evaluating Safety and Efficacy of a Fixed Dose Combination of Remogliflozin Etabonate, Vildagliptin, and Metformin in Indian Patients with Type 2 Diabetes Mellitus (Triad-RMV)” to ‘Clinical Diabetes and Endocrinology’ effective from the date of submission.We affirm that the manuscript is original, that we are the authors of the manuscript, and that it has not been published previously nor is it under consideration for publication elsewhere. We also affirm that the manuscript does not infringe upon any existing copyright or any other rights of any third party and that we have obtained all necessary permissions for any third-party materials included in the manuscript.
: Corresponding author has received funding from Glenmark Pharmaceuticals Ltd for research and its publication. The other authors declare that they have no competing interests.
